NCT02525991View on ClinicalTrials.gov

Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting

PHASE4CompletedINTERVENTIONAL

Enrollment

323

Participants

Timeline

Start Date

September 8, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions

Agitation

Interventions

DEVICE

Staccato® Delivery System Loxapine (ADASUVE®)

one dose Loxapine Staccato 9.1 mg

Trial Locations (1)

08028

Ferrer Internacional S.A., Barcelona

All Listed Sponsors

lead

Ferrer Internacional S.A.

INDUSTRY

NCT02525991 - Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting | Biotech Hunter | Biotech Hunter